Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among Covid-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation.
Developed by Celon’s in-house R&D team in a record three weeks, the emulsion-based formulation will provide leading hospitals and Covid-19 treatment centers with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.
Celon Labs’ Managing Director, Mr. M. Nagesh Kumar, spoke of Celon’s role during India’s second wave of COVID-19: “Celon Labs is deeply committed to supporting the ongoing efforts to combat the Covid-19 pandemic during this deadly second wave and to save as many lives as possible. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the domestic market soon.”
Additionally, the Chairman of Celon, Mr. Hocine Sidi-Said, expressed his gratitude to employees for achieving this important milestone: “I am delighted to see that Celon Labs has mobilized its talents and expertise to swiftly respond to this pressing medical need. I am grateful to the team at Celon Labs who have made the launch of Amphotericin B Emulsion possible.”